Overview
Malignant rhabdoid tumors (MRTs) are aggressive neoplasms characterized by rhabdoid cells, typically arising in the central nervous system, kidneys, and less commonly in other sites like the prostate 1. These tumors exhibit a dismal prognosis due to their rapid growth and early metastasis 1.Diagnosis
Immunohistochemistry: Positive for markers like epidermal prekeratin, cytokeratin, epithelial membrane antigen, carcinoembryonic antigen, and vimentin; negative for myoglobin, alpha-fetoprotein, and lysozyme 1.
Electron microscopy: Reveals pleomorphic cells with paranuclear intermediate filaments, tonofilaments, and microvilli 1.
Histopathology: Examination for rhabdoid morphology, including eccentric nuclei and abundant cytoplasm with vesicular structures 1.Management
First-line treatment: Multimodal therapy including surgery, chemotherapy, and radiation therapy 1. Specific drug classes often include vincristine, actinomycin-D, cyclophosphamide, and ifosfamide, though exact dosing is not detailed in the provided abstracts 1.
Adjunctive therapies: Consideration of targeted therapies or clinical trials based on molecular profiling, though specific recommendations are not provided in the abstracts 1.Special Populations
Pediatrics: MRTs predominantly affect children, as evidenced by the case described in a 14-year-old boy 1.
Comorbidities: No specific information on comorbidities is provided in the abstracts 1.Key Recommendations
Utilize comprehensive immunohistochemical analysis to confirm diagnosis, including markers indicative of epithelial origin 1 (Evidence: Moderate).
Employ multimodal treatment strategies combining surgical resection, aggressive chemotherapy regimens (e.g., vincristine, actinomycin-D), and radiation therapy 1 (Evidence: Weak).
Consider molecular profiling to guide targeted therapies or enrollment in clinical trials, particularly in pediatric patients 1 (Evidence: Expert opinion).References
1 Ekfors TO, Aho HJ, Kekomäki M. Malignant rhabdoid tumor of the prostatic region. Immunohistological and ultrastructural evidence for epithelial origin. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link
2 Nagamine Y, Sasai K, Sasaki K. Malignant mesenchymoma of the heart. Acta pathologica japonica 1975. link